How should I manage a headache that occurs while receiving secukinumab (Cosentyx) therapy?

Management of Headache During Secukinumab Therapy

Treat secukinumab-associated headache with standard acute headache protocols: start with ibuprofen 400 mg or acetaminophen 1000 mg for mild-to-moderate headache, and add a triptan for moderate-to-severe episodes that do not respond to simple analgesics. Headache is a recognized adverse event with secukinumab, occurring commonly alongside nasopharyngitis and upper respiratory infections 1, 2.

Acute Treatment Algorithm

First-Line Therapy

• Begin with NSAIDs or acetaminophen as initial management for headache occurring during secukinumab treatment 3, 4:
  • Ibuprofen 400 mg is effective for tension-type headaches 5, 4
  • Acetaminophen 1000 mg per dose (maximum 4 g/day) is an alternative 5, 3
  • NSAIDs should be limited in patients with chronic kidney disease 5

Escalation for Moderate-to-Severe Headache

• Add a triptan when simple analgesics fail to provide adequate relief 3, 4:
  • Any triptan (sumatriptan, rizatriptan, eletriptan, almotriptan, naratriptan, frovatriptan, zolmitriptan) is appropriate 3, 4
  • Combine triptan + NSAID for superior efficacy: this combination yields approximately 130 additional patients per 1,000 achieving sustained pain relief at 48 hours versus triptan alone 4
  • Triptan + acetaminophen is less effective than triptan + NSAID but remains a reasonable option 3, 4

Refractory Cases

• CGRP receptor antagonists (gepants) such as rimegepant, ubrogepant, or zavegepant are appropriate when triptan + NSAID combinations fail 3, 4
• Lasmiditan is reserved as a last-resort acute agent 3, 4

Preventive Therapy Considerations

• Initiate preventive medication if headaches occur ≥2 times per month causing ≥3 days of disability 3:
  • First-line preventive options include propranolol (80–240 mg/day), amitriptyline (30–150 mg/day), topiramate, or CGRP monoclonal antibodies 3
  • CGRP monoclonal antibodies (galcanezumab, fremanezumab, eptinezumab) or oral CGRP antagonist atogepant have favorable safety profiles 5

Critical Safety Considerations

• Avoid opioids and butalbital-containing compounds entirely, as they increase risk of dependency and medication-overuse headache 3, 4
• Screen for medication-overuse headache (MOH): ≥15 days/month of NSAID use or ≥10 days/month of triptan use defines overuse 3, 4
• Add antiemetics (metoclopramide or prochlorperazine) when nausea is prominent 3, 4
• Consider non-oral triptan formulations (nasal spray or subcutaneous) when severe nausea impedes oral absorption 3, 4

Non-Pharmacologic Adjuncts

• Aerobic exercise and physical therapy provide preventive benefit for both tension-type headache and migraine without drug-interaction risks 5, 3
• Reinforce lifestyle modifications: adequate hydration, regular meals, consistent sleep patterns, and stress management 3, 4

Context: Secukinumab Safety Profile

• Headache is among the most frequently reported adverse events with secukinumab, typically mild to moderate in severity 1, 2
• The overall safety profile of secukinumab shows nasopharyngitis, headache, and upper respiratory tract infections as the most common events 6, 1, 2
• Do not discontinue secukinumab solely for headache; instead, manage the headache symptomatically using the algorithm above, as headache does not represent a contraindication to continued therapy 6, 1, 2